Effective July 1, 2022, Sanofi has lowered the out-of-pocket cost of its insulin products to $35 for a 30-day supply through the company’s insulins Valyou Savings Program.
Previously, the program offered its insulins for $99. This includes Toujeo (insulin glargine), Lantus (insulin glargine), Admelog (insulin lispro), and Apidra (insulin glulisine). The program does not include Sanofi combination insulin product Soliqua (insulin glargine and lixisenatide). The program is open to anyone regardless of income. Sanofi also recently launched Insulin Glargine Injection U-100 at a price that is 60% less than the current Lantus list price.

Other pharmaceutical companies lowering the cost of insulins include Lilly and Novo Nordisk.

• Lilly announced in September 2021 that it was lowering the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective Jan. 1, 2022. Those using Lilly insulins can now fill their monthly prescription for $35 through the Lilly Insulin Value Program for people with commercial insurance or who are uninsured, and the Senior Savings Model for seniors in participating Medicare Part D plans.
• Novo Nordisk also offers lower cost insulins, including a 30-day supply of a combination of Novo Nordisk insulin products (up to three vials or two packs of pens) for $99 for eligible patients. Additionally, Novo Nordisk human insulin is available at national pharmacies like Walmart and CVS for about $25 per vial.

Click here to read the full article.